Metabolic profiling in liver microsomes and mice of E28, a potent FLT3 inhibitor

References

• Cao X-C, Guo M-F, Han Y, Fan Y-T, Zhu J-H, Zhu H, Xu J-D, Shen H, Zhou G-R, Mao Q, et al. 2021. Systematic metabolite profiling of N-acetyldopamine oligomers from Cicadae Periostracum in rats by ultra-high performance liquid chromatography coupled with quadrupole-time-of-flight mass spectrometry. J Pharm Biomed Anal. 192:113665
   PubMed Web of Science ®Google Scholar
• Cerchione C, Peleteiro Raíndo A, Mosquera Orgueira A, Mosquera Torre A, Bao Pérez L, Marconi G, Isidori A, Pérez Encinas M, Martinelli G. 2021. Safety of FLT3 inhibitors in patients with acute myeloid leukemia. Expert Rev Hematol. 14(9):851–865.
   PubMed Web of Science ®Google Scholar
• Chen X, Xu L, Guo S, Wang Z, Jiang L, Wang F, Zhang J, Liu B. 2019. Profiling and comparison of the metabolites of diosmetin and diosmin in rat urine, plasma and feces using UHPLC-LTQ-orbitrap MSn. J Chromatogr B Analyt Technol Biomed Life Sci. 1124:58–71.
   PubMed Web of Science ®Google Scholar
• Garitano-Trojaola A, Sancho A, Götz R, Eiring P, Walz S, Jetani H, Gil-Pulido J, Da Via MC, Teufel E, Rhodes N, et al. 2021. Actin cytoskeleton deregulation confers midostaurin resistance in FLT3-mutant acute myeloid leukemia. Commun Biol. 4(1):799and
   PubMed Web of Science ®Google Scholar
• Hou H, Tien H. 2020. Genomic landscape in acute myeloid leukemia and its implications in risk classification and targeted therapies. J Biomed Sci. 27(1):81.
   PubMed Web of Science ®Google Scholar
• Hu M, Li Y, You F, Bai J, Fan X, Zhao S, Sun Y, Wang B, Hu J, Li Y. 2020. Comparison and identification of metabolic profiling of bicyclol in rats, dogs and humans in vitro and in vivo. Eur J Pharm Sci: Off J Eur Fed Pharm Sci. 154:105518.
   PubMed Web of Science ®Google Scholar
• Hu T, Ge X, Wang J, Zhang N, Diao X, Hu L, Wang X. 2021. Metabolite identification of iridin in rats by using UHPLC-MS/MS and pharmacokinetic study of its metabolite irigenin. J Chromatogr B Analyt Technol Biomed Life Sci. 1181:122914.
   PubMed Web of Science ®Google Scholar
• Huang M, Cheng Z, Wang L, Feng Y, Huang J, Du Z, Jiang H. 2018. A targeted strategy to identify untargeted metabolites from in vitro to in vivo: rapid and sensitive metabolites profiling of licorice in rats using ultra-high performance liquid chromatography coupled with triple quadrupole-linear ion trap mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 1092:40–50.
   PubMed Web of Science ®Google Scholar
• Infante M, Piris M, Hernández-Rivas J. 2018. Molecular alterations in acute myeloid leukemia and their clinical and therapeutical implications. Med Clin (Barc). 151(9):362–367.
   PubMed Web of Science ®Google Scholar
• Kayser S, Levis M. 2022. Updates on targeted therapies for acute myeloid leukaemia. Br J Haematol. 196(2):316–328.
   PubMed Web of Science ®Google Scholar
• Liu P, Wu S, Dong Z. 2021. Identification of the metabolites of tofacitinib in liver microsomes by liquid chromatography combined with high resolution mass spectrometry. Biomed Chromatogr. 35(6):e5081.
   PubMed Web of Science ®Google Scholar
• Marjoncu D, Andrick B. 2020. Gilteritinib: a novel FLT3 inhibitor for relapsed/refractory acute myeloid leukemia. J Adv Pract Oncol. 11(1):104–108.
   PubMedGoogle Scholar
• Patnaik M. 2018. The importance of FLT3 mutational analysis in acute myeloid leukemia. Leuk Lymphoma. 59(10):2273–2286.
   PubMed Web of Science ®Google Scholar
• Rummelt C, Gorantla SP, Meggendorfer M, Charlet A, Endres C, Döhner K, Heidel FH, Fischer T, Haferlach T, Duyster J, et al. 2021. Activating JAK-mutations confer resistance to FLT3 kinase inhibitors in FLT3-ITD positive AML in vitro and in vivo. Leukemia. 35(7):2017–2029.
   PubMed Web of Science ®Google Scholar
• Scheers E, Borgmans C, Keung C, Bohets H, Wynant I, Poggesi I, Cuyckens F, Leclercq L, Mamidi R. 2021. Metabolism and disposition in rats, dogs, and humans of erdafitinib, an orally administered potent pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor. Xenobiotica. 51(2):177–193.
   PubMed Web of Science ®Google Scholar
• Scholl S, Fleischmann M, Schnetzke U, Heidel F. 2020. Molecular mechanisms of resistance to FLT3 inhibitors in acute myeloid leukemia: ongoing challenges and future treatments. Cells. 9(11):2493.
   PubMed Web of Science ®Google Scholar
• Seipel K, Marques M, Sidler C, Mueller B, Pabst T. 2018. MDM2- and FLT3-inhibitors in the treatment of FLT3-ITD acute myeloid leukemia, specificity and efficacy of NVP-HDM201 and midostaurin. Haematologica. 103(11):1862–1872.
   PubMed Web of Science ®Google Scholar
• Tang J, Shi M, Xu Y, Ju Z, Guan H, Lin J, Li G, Han H, Zhang T. 2021. Metabolite profiling of Shuganzhi tablets in rats and pharmacokinetics study of four bioactive compounds with liquid chromatography combined with electrospray ionization tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 1179:122827.
   PubMed Web of Science ®Google Scholar
• Wang A, Li X, Chen C, Wu H, Qi Z, Hu C, Yu K, Wu J, Liu J, Liu X, et al. 2017. Discovery of 1-(4-(4-Amino-3-(4-(2-morpholinoethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)-3-(5-(tert-butyl)isoxazol-3-yl)urea (CHMFL-FLT3-213) as a highly potent type II FLT3 kinase inhibitor capable of overcoming a variety of FLT3 kinase mutants in FLT3-ITD positive AML. J Med Chem. 60(20):8407–8424.
   PubMed Web of Science ®Google Scholar
• Yuan X, Chen Y, Zhang W, He J, Lei L, Tang M, Liu J, Li M, Dou C, Yang T, et al. 2019. Identification of Pyrrolo [2,3- d] pyrimidine-based derivatives as potent and orally effective FMS-like tyrosine receptor kinase 3 (FLT3) inhibitors for treating acute myelogenous leukemia. J Med Chem. 62(8):4158–4173.
   PubMed Web of Science ®Google Scholar